

Zoledronic Acid

Indication

Palliative therapy for and prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.

Adjuvant therapy for postmenopausal women with node-positive invasive breast cancer or node-negative invasive breast cancer and at high risk of recurrence.

Please refer to 'Bone Protection Myeloma 2020' protocol for myeloma patients

ICD-10 codes

Codes with a prefix C15-C80

Regimen details

Day	Drug	Dose	Route
1	Zoledronic acid	4mg*	IV infusion

* dose to be reduced in renal impairment (CrCl \leq 60mL/min) – see renal impairment section.

Cycle frequency

Palliative therapy: 21-28 days

Adjuvant therapy for breast cancer: 6 monthly

Number of cycles

Palliative therapy: as indicated

Adjuvant therapy for breast cancer: up to 3 years

Administration

Zoledronic acid is administered by IV infusion in 100mL 0.9% sodium chloride over 15 minutes.

Pre-medication

Ensure patients are well hydrated prior to treatment.

Emetogenicity

This regimen has low emetic potential

Additional supportive medication

Oral calcium and vitamin D supplements – UK chemotherapy board guidelines recommend 1000mg calcium and 800IU vitamin D daily. Dose adjusted according to calcium levels.

Paracetamol for flu-like symptoms as required.

Antiemetics if required.

Extravasation

Zoledronic acid is not vesicant

Investigations – pre first cycle

ALL PATIENTS ARE RECOMMENDED TO HAVE A DENTAL ASSESSMENT PRIOR TO COMMENCING TREATMENT (RISK OF OSTEONECROSIS OF THE JAW)

Investigation	Validity period (or as per local policy)
U+E (including creatinine)	7 days
Calcium	7 days
Phosphate	7 days
Magnesium	7 days
Vitamin D	14 days

Investigations - pre subsequent cycles

Investigation	Validity period (or as per local policy)
U+E (including creatinine)	7 days
Calcium	7 days
Phosphate	7 days
Magnesium	Every 3 months

6 monthly dental assessment is recommended.

Standard limits for administration to go ahead

If blood results within normal range, administer Zoledronic acid as planned. If outside of normal limits refer to table below:

Investigation	Result	Action
Calcium	<2.2 mmol/L corrected	DO NOT ADMINISTER – inform prescriber/consultant
	>2.6 -3.0mmol/L corrected	Administer Zoledronic acid and advise patient to stop calcium supplement
	>3.0mmol/L corrected	DO NOT ADMINISTER – refer for urgent management of hypercalcaemia
Magnesium	0.5-0.7mmol/L	Administer Zoledronic acid
	<0.5mmol/L	DO NOT ADMINISTER – Inform prescriber/consultant
Phosphate	0.6-0.8 mmol/L	Administer Zoledronic acid
	<0.6mmol/L	DO NOT ADMINISTER – Inform prescriber/consultant
Vitamin D (prior to 1 st dose only)	<35nmol/l	DO NOT ADMINISTER - Inform prescriber, commence high dose replacement as per local practice, delay treatment to allow at least 2 weeks high dose replacement. No need to recheck level.
	35-50nmol/l	Administer Zoledronic acid. Inform prescriber - consider increasing calcium/vitamin D supplementation to twice daily.
	>50nmol/l	Administer Zoledronic acid
Dental work	Check with patient prior to each treatment. If they have had any dental work done since previous treatment, do not administer zoledronic acid and inform consultant. It is recommended that patients should have a 6 monthly dental assessment	

Dose modifications

• Renal impairment

Creatinine clearance should be calculated prior to each dose. The dose should then be adjusted as per table below. If CrCl < 30mL/min Zoledronic acid is contra-indicated.

CrCl (mL/min)	Zoledronic Acid dose
>60	4mg
50-60	3.5mg
40-49	3.3mg
30-39	3.0mg
<30	Omit

• Hepatic impairment

Limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population.

Adverse effects - for full details consult product literature/ reference texts

• Serious side effects

Osteonecrosis of the jaw (dental assessment prior to treatment and withhold zoledronic acid for 4 weeks pre and post any dental intervention). If dental extractions are required the patient should be referred to a specialist dental hospital

Atrial fibrillation

• Frequently occurring side effects

Flu like symptoms

Pain flare

Bone pain, myalgia, arthralgia

Hypocalcaemia

Hypophosphataemia

Nausea

• Other side effects

Numbness around mouth (sign of low calcium)

Conjunctivitis

Headache

Renal impairment

Anaemia

Significant drug interactions – for full details consult product literature/ reference texts

Thalidomide: Increased risk of renal impairment with concomitant thalidomide

Aminoglycosides: Increased risk of renal impairment

Anti-angiogenics: increased incidence of osteonecrosis of the jaw has been reported

Additional comments

Note the onset of treatment effect is 2-3 months.

References

- Summary of Product Characteristics Zoledronic acid (Seacross) accessed 7 Oct 2021 via [medicines.org.uk](https://www.medicines.org.uk)
- UK Chemotherapy Board. *Medication-related osteonecrosis of the jaw. Guidance for the oncology multidisciplinary team*. Report of a working party on behalf of the UK Chemotherapy Board. UKCB, 2019.

Written/reviewed by: Dr S Spensley (Consultant Oncologist, Taunton and Somerset NHS Trust), Dr G Ayre (Consultant Oncologist, UHBW NHS Trust)

Checked by: Kate Gregory (Lead Pharmacist for SACT protocols, SWAG Cancer Alliance)

Authorised by: Dr Jeremy Braybrooke (Consultant Oncologist, UHBW NHS Trust and SWAG Cancer Alliance)

Date: October 2021
